ID
13603
Descripción
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00510939
Link
https://clinicaltrials.gov/show/NCT00510939
Palabras clave
Versiones (1)
- 19/2/16 19/2/16 -
Titular de derechos de autor
CC BY-NC 3.0
Subido en
19 de febrero de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Acute Myeloid Leukemia NCT00510939
Eligibility Acute Myeloid Leukemia NCT00510939
- StudyEvent: Eligibility
Descripción
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Descripción
1. serum bilirubin 2 x> upper limit of normal (uln)
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1278039
Descripción
2. aspartate aminotransferase (ast/sgot) or alanine aminotransferase (alt/sgpt) >3.5 x uln
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0201836
- UMLS CUI [2]
- C0201899
Descripción
3. serum creatinine ³ 2.5 x uln or 24-hour creatinine clearance £ 60 ml/min (measured or calculated by cockcroft-gault)
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0201976
- UMLS CUI [2]
- C0373595
Descripción
4. patients with aml of fab m3 classification (apl)
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0023487
Descripción
5. patients with a history of another primary malignancy within the previous 1 year other than basal cell carcinoma or carcinoma in situ, the patient is in remission
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0006826
Descripción
6. any clinically defined central nervous system aml.
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1332884
- UMLS CUI [2]
- C0023467
Descripción
7. participation in an investigational drug study within the 30 days prior to entry
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C2348568
Descripción
8. evidence of uncontrolled infection or cns-hemorrhagic
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0009488
Descripción
9. patients with documented cases of human immunodeficiency virus (hiv)
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0019682
Descripción
10. peripheral neuropathy or neuropathic pain grade > or = 2
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0031117
- UMLS CUI [2]
- C0458960
Descripción
11. has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C0006030
- UMLS CUI [2,1]
- C0020517
- UMLS CUI [2,2]
- C0024730
- UMLS CUI [3,1]
- C0020517
- UMLS CUI [3,2]
- C0019134
Descripción
12. uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, new york heart association (nyha) class iii or iv heart failure (attachment 7,nyha classification of cardiac disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C0018799
Descripción
13. rasgrp1/aptx gene expression ratio calculated at the screening <10 (part b.2 only)
Tipo de datos
boolean
Alias
- UMLS CUI [1]
- C1419283
- UMLS CUI [2]
- C1423885
Similar models
Eligibility Acute Myeloid Leukemia NCT00510939
- StudyEvent: Eligibility
C0023467 (UMLS CUI [2,1])
C1518321 (UMLS CUI [2,2])
C0392920 (UMLS CUI [3,1])
C3841806 (UMLS CUI [3,2])
C0035020 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
C0392920 (UMLS CUI [2])
C0232970 (UMLS CUI [2])
C1423885 (UMLS CUI [2])
C0201899 (UMLS CUI [2])
C0373595 (UMLS CUI [2])
C0023467 (UMLS CUI [2])
C0458960 (UMLS CUI [2])
C0006030 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0024730 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0019134 (UMLS CUI [3,2])
C1423885 (UMLS CUI [2])
Sin comentarios